Veradermics, Incorporated MANE 深 滬
等待開盤 02-06 09:30:00 美东时间
37.16
-0.590
-1.56%
華盛通- 最 高40.11
- 今 開38.23
- 成交量 93.47万股
- 最 低 35.09
- 昨 收 37.75
- 總市值 0
- 52周最高 40.11
- 市盈率 靜 --
- 換手率 Infinity.00%
- 52周最低 32.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 40.11
- 量 比 0
- 振 幅 13.30%
- 歷史最低 32.00
- 每 手 1
- 風險率 10.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 芯科实验室飙升近49%！德州仪器以75亿美元展开收购；Enphase能源绩后大涨近39%，Q4业绩及26Q1指引均超预期
芯科实验室飙升近49%！德州仪器以75亿美元展开收购；Enphase能源绩后大涨近39%，Q4业绩及26Q1指引均超预期；鲍威尔工业涨逾16%，电力业务进军数据中心领域>>
02-05 15:50
植发药物开发商Veradermics(MANE.US)IPO定价17美元/股 上市首日暴涨122%
植发药物开发商Veradermics上市首日收涨逾122%，报37.75美元，远高于其首次公开募股(IPO)的发行价17美元。
02-05 09:18
Veradermics surges on public debut after upsized offering
Veradermics (MANE), a developer of an oral hair loss therapy, more than doubled in value in its first trading session on Wednesday as the company made its public debut following an upsized offering of...
02-05 03:31
BRIEF-Veradermics Says It Prices Of Upsized Initial Public Offering At $17 Per Share
BRIEF-Veradermics Says It Prices Of Upsized Initial Public Offering At $17 Per Share Feb 3 (Reuters) - Veradermics Inc MANE.N : VERADERMICS ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING VERADERMICS INC - PRICES UPSIZED IPO AT $17 PER SHARE VERADERMICS INC: PRICING OF ITS UPSIZED INITIAL PUBLI
02-04 10:58
“秃头经济”新玩家：生发药企Veradermics(MANE.US)拟IPO募资2.14亿美元，市值冲刺5.34亿
Veradermics 公司正寻求通过首次公开募股筹集高达 2.136 亿美元，以帮助其生发药实现商业化。
01-29 11:30
BRIEF-Veradermics To Offer 13.4 Million Shares In IPO - SEC Filing
BRIEF-Veradermics To Offer 13.4 Million Shares In IPO - SEC Filing Jan 28 (Reuters) - Veradermics Inc MANE.N : VERADERMICS INC - TO OFFER 13.4 MILLION SHARES IN IPO - SEC FILING VERADERMICS INC - IPO PRICE EXPECTED BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING VERADERMICS: WELLINGTON MANAGEMENT I
01-29 02:08
UPDATE 3-Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO
UPDATE 3-Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO Adds analyst comment in paragraphs 5,9 By Arasu Kannagi Basil Jan 28 (Reuters) - Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, is targeting a valuation of up to $908.2 million in its initial
01-28 19:16
